NCT01849250已完成2 期
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 65
- 试验地点
- 4
- 主要终点
- Normal Breast Tissue Expression of Tumor Necrosis Factor Alpha (TNF-alpha) Levels
研究概览
简要总结
This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.
详细描述
PRIMARY OBJECTIVES:
I. To determine whether treatment with docosahexaenoic acid (DHA) for 12 weeks at 1000 mg twice daily as compared to placebo reduces normal breast tissue levels of tumor necrosis factor-alpha (TNF-alpha) in overweight and obese patients with a history of stage I-III invasive breast cancer, ductal carcinoma in situ (DCIS), Paget's disease, lobular carcinoma in situ (LCIS), or proliferative benign breast disease.
SECONDARY OBJECTIVES:
I. To investigate the effect of DHA at 1000 mg twice daily on tissue biomarkers
- Change from the baseline in cyclooxygenase-2 (COX-2)/interleukin-1-beta (IL-1beta)/aromatase measured by quantitative real-time polymerase chain reaction (PCR).
- Change from the baseline in crown-like structures of the breast (CLS-B) measured by immunohistochemical techniques for cluster of differentiation (CD)68.
- Change from baseline in CLS-B index determined as follows: ([number of slides with evidence of at least one CLS-B]/[total number of slides examined]).
- Change from baseline in CLS-B/cm^2 defined as the number of CLS-B/cm^2. II. Evaluate age as a predictor of CLS-B and inflammatory biomarkers (TNF-alpha/COX-2/IL-1beta) at baseline and over the time of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Participants must have a history of histologically-confirmed stage I-III invasive breast cancer or ductal carcinoma in situ (DCIS), Paget's disease, lobular carcinoma in situ (LCIS), or proliferative benign breast disease
- •No evidence of disease (in situ or invasive cancer that would normally be treated by resection) at trial entry as determined by the investigator
- •>= 6 months from all previous breast cancer treatment (including surgery for invasive cancer, chest wall radiotherapy, chemotherapy, trastuzumab and endocrine therapy)
- •Participants must have a body mass index (BMI) >= 25, defined as (weight in kilograms/[height in meters]^2)
- •Participants must have adequate accessible breast tissue as determined by the treating physician, consisting of one breast unaffected by invasive cancer, which has not been radiated; a history of prior pre-invasive breast cancer or benign biopsy of this breast will be permitted
- •Daily DHA consumption =< 200 mg/day in the month prior to screening estimated by an abbreviated DHA food frequency questionnaire
- •Mammogram within no more than 6 months prior to the date of informed consent (normal/benign Breast Imaging-Reporting and Data System [BI-RADS] 1 or 2) and no further routine breast imaging planned during the course of the study (12 weeks DHA/placebo)
- •Eastern Cooperative Oncology Group (ECOG) performance status must be =< 2 (Karnofsky >= 60%)
- •Absolute neutrophil count >= 1,500/uL
- •Platelets >= 75,000/uL
- •White blood cells >= 3,000/uL
- •Hemoglobin >= 10 g/dL
- •Total bilirubin within 1.5 times the institution's upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) within 1.5 times the institution's ULN
- •Serum creatinine within 1.5 times the institution's ULN
- •Pregnant women will be excluded; for women of childbearing potential; negative pregnancy testing within 72 hours prior to or on study visit #1 (day 0) and willingness to use adequate contraception during the study intervention OR post-menopausal defined as any one of the following 1) prior hysterectomy, 2) absence of menstrual period for 1 year in the absence of prior chemotherapy or 3) absence of menstrual period for 2 years in women with a prior history of chemotherapy exposure who were pre-menopausal prior to chemotherapy
- •Willingness to comply with all study interventions and follow-up procedures including the ability to swallow the study drug
- •Ability to understand and the willingness to sign a written informed consent document
排除标准
- •Any type of active invasive cancer (excluding breast and non-melanoma skin cancer) within the preceding 18 months
- •A history of histologically-confirmed bilateral invasive breast cancer
- •Bilateral mastectomy
- •Prior history or evidence of metastatic breast cancer
- •Prior radiation therapy to the contralateral (unaffected) breast
- •Prior history of contralateral (unaffected) breast augmentation with breast implant placement
- •History of daily use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) in the week preceding study entry
- •History of DHA supplementation > 200 mg/day in the month preceding study entry
- •History of autoimmune disorder or any illness that requires therapy with chronic steroids or immunomodulators
- •History of therapeutic doses of anticoagulants including warfarin and low molecular weight heparin (e.g. for prior deep venous thrombosis and pulmonary embolism) in the preceding year
- •Participants may not be receiving any other investigational agents during the study
- •Women who have received cancer surgery, chemotherapy, biological therapy (e.g., trastuzumab), or radiotherapy for the treatment of any cancer within 6 months of study participation
- •Women who are receiving endocrine therapy for breast cancer treatment or chemoprevention including tamoxifen, letrozole, anastrozole, fulvestrant, or exemestane at the time of screening
- •Individuals with severe underlying chronic illness, such as uncontrolled diabetes; ongoing or active infection, psychiatric illness or social situations which in the opinion of the investigator would interfere with study participation
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to DHA or corn/soy oil in placebo agent
- •Pregnant, breastfeeding, or women of childbearing potential unwilling to use a reliable contraceptive method
研究组 & 干预措施
Arm I (Docosahexaenoic Acid)
Experimental
Docosahexaenoic Acid orally twice a day (PO BID) for 12 weeks.
干预措施: Docosahexaenoic Acid (Drug)
Arm II (placebo)
Placebo Comparator
Placebo orally twice a day (PO BID) for 12 weeks.
干预措施: Placebo (Other)
结局指标
主要结局
Normal Breast Tissue Expression of Tumor Necrosis Factor Alpha (TNF-alpha) Levels
时间窗: Baseline to 12 weeks
Differences in normal breast tissue levels of TNF-α 12 weeks post-treatment relative to pre-treatment for active treatment and placebo arm, compared using analysis of covariance where the post-treatment measurements were used as a dependent variable and the pretreatment measurements were included as a covariate in the analysis. For the primary study end-point TNF-α levels will be measured by quantitative real-time PCR (mRNA essays) on extracted RNA from breast core biopsies. Relative expression determined using the Computed Tomography (ΔΔCT) analysis protocol.
次要结局
- Number of Participants With Crown-like Structures of the Breast (CLS-B) at Baseline and Post-treatment(Baseline to 12 weeks)
- Red Blood Cell (RBC) Fatty Acid Level as a Surrogate of Compliance(Baseline and week 12)
- Absolute Change in CLS-B/cm^2 Adjusted for the Pre-treatment Measurements(Baseline to 12 weeks)
- Breast Tissue Cox 2 mRNA Levels at Baseline and 12 Weeks(Baseline to 12 weeks)
- Mean Difference in the Breast Tissue IL- Beta mRNA Levels of Tissue Biomarkers(Baseline to 12 weeks)
- Mean Difference in the Breast Tissue Aromatase mRNA Levels of Tissue Biomarkers(Baseline and 12 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Memory Improvement With Docosahexaenoic Acid Study (MIDAS)Age-Related Cognitive DeclineAge-Related Memory DisordersNCT00278135DSM Nutritional Products, Inc.485
已完成
1 期
A Dose Response Investigation of Docosahexaenoic Acid (DHA)Nutrition, HealthyNCT06294067University of Toronto72
已完成
2 期
Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm LaborPregnant Women Diagnosed With Threatened Preterm LaborNCT06302023Khon Kaen University60
Unknown
2 期
High Dose Omega 3 in People at Risk for DementiaInflammationMild Cognitive ImpairmentCognitive DeclineSCDCognitive DysfunctionPathologic ProcessesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersDementiaCognition DisordersMental DisorderNCT03926351University Hospital, Akershus40
已完成
1 期
Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm NeonatesNecrotizing EnterocolitisNCT01745510Coordinación de Investigación en Salud, Mexico225